Navigation Links
Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
Date:4/29/2009

al development.

TARGIT is Archimedes' proprietary technology for the delivery of drugs to specific regions of the large intestine or the local treatment of disease, an area of great interest to the pharmaceutical industry. The TARGIT system offers the option of delivering high local concentrations of drug, which are ideal for the topical treatment of diseases such as ulcerative colitis, Crohn's disease, irritable bowel syndrome and bacterial infections. The ability of TARGIT to reliably deliver drugs into the lower GIT has been demonstrated in numerous clinical studies.

    For more information, please visit:http://www.archimedespharma.com

    For further information, please contact:
    Pharmalink:
    Johan Haggblad, Managing Director, +46(0)70-668-0644
    Email: johan.haggblad@pharmalink.se
   http://www.pharmalink.se

    Archimedes Pharma:
    Michael Clark, +44-118-931-5077
   http://www.archimedespharma.com

    Citigate Dewe Rogerson (Pharmalink):
    Chris Gardner/Nina Enegren, +44-207-638-9571
    CapitalMSL (Archimedes):
    Mary Clark, Tel: +44-207-3075330



'/>"/>
SOURCE Pharmalink AB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
2. China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
3. NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
6. Gen-Probe Completes Acquisition of Tepnel Life Sciences
7. Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations
8. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free
9. Atritech Completes $30 Million Financing
10. Roche Completes Tender Offer for Genentech
11. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... of circulating tumor cells (CTCs) in a mouse model ... in several groups of CTCs, including significant differences from ... to generate metastases. In their study reported in ... investigators from the Massachusetts General Hospital (MGH) Cancer Center ... unexpected factors that may prove to be targets for ...
(Date:9/22/2014)... developed a unique nanoscale device that for the ... discovery could have major implications for creating faster ... communication. , The research paper by University of ... Li and his graduate student Huan Li has ... October issue of Nature Nanotechnology . , ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Lawrence ... President John DeGioia on Friday renewed their institutional ... an additional five years to expand the collaborative ... nonproliferation and global climate, energy and environmental sciences. ... an MOU originally signed in December 2009 and ...
(Date:9/22/2014)... Sept. 22, 2014 US demand to rise ... specialty biocides is forecast to rise 3.9 percent per ... demand is projected to increase 1.3 percent per year ... strong rebound in construction expenditures will support demand for ... markets, while growth in consumer spending and manufacturing output ...
Breaking Biology Technology:Massachusetts General study reveals gene expression patterns in pancreatic CTCs 2Massachusetts General study reveals gene expression patterns in pancreatic CTCs 3Engineers show light can play seesaw at the nanoscale 2Lawrence Livermore Renews Pact with Georgetown University to Expand Research and Education in Science and Policy 2US Biocides Market 2US Biocides Market 3
... and PHILADELPHIA, July 4 ,Shire Limited (LSE:SHP, NASDAQ: SHPGY), ... earnings on,Thursday 31 July 2008, Results press ... BST / 07:00 EDT Investor meeting and conference ... Investor & Analyst meeting and conference call:, Angus ...
... Research Group has,released results from aboratory testing ... at Oregon State University which,demonstrated the Eniva ... for human cells. This third party testing ... effort to further identify,mechanisms by which the ...
... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) today announced that ... its cash burn rate. As previously,announced, the Company ... acquisitions and mergers. In conjunction with this,process, the ... its VP,series of drugs, and has determined that ...
Cached Biology Technology:Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008 2Eniva VIBE(R) Nutraceutical Tested at Linus Pauling Micronutrient Research Institute and Found to Possess DNA Protective Properties 2Vasogen Provides Corporate Update 2
(Date:9/21/2014)... new strains of bacteria have emerged that resist even ... drug-resistant forms of tuberculosis and staphylococcus, infect more than ... Despite the urgent need for new treatments, scientists have ... past decade. , MIT engineers have now turned a ... system that can disable any target gene, they have ...
(Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
(Date:9/19/2014)... University of Oklahoma biology professor will study the unique ... that could eventually benefit people,s health. The OU ... the energy required to produce the signals used to ... electric signals at a rate of 500-600 discharges a ... for the electric fish are extreme, but necessary for ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... Hidenori Ichijo and Hideki Nishitoh (The University of Tokyo) ... genetics of ALS. Amyotrophic lateral sclerosis (ALS), also ... fatal neurological disease involving the degeneration and death of ... the most common neuromuscular diseases worldwide, affecting as roughly ...
... sturgeons, more caviar will be exported from Caspian Sea ... of unacceptably permissive new trade quotas announced Thursday by ... Most sturgeon species are endangered and some, like beluga ... damage this ancient fish,s chance of recovery and survival, ...
... New research* shows that while engineered nanomaterials can ... food chain from single celled organisms to higher ... and there was no evidence of the nanomaterials ... results observed by researchers from the National Institute ...
Cached Biology News:New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 2New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 3New CITES quotas allow more caviar export, further jeopardize endangered sturgeon 4Research measures movement of nanomaterials in simple model food chain 2
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
Weinreb Linker...
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Biology Products: